Date: 2017-09-28
Type of information: Licensing agreement
Compound: Zevtera®/Mabelio® (ceftobiprole)
Company: Basilea Pharmaceutica (Switzerland) China Resources Gosun Pharmaceutical (China)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
- antibiotic/cephalosporin. Ceftobiprole belongs to the class of antibacterial agents known as cephalosporins. Its broad spectrum activity encompasses Gram-positive and Gram-negative bacteria, including anti-pseudomonal activity similar to cefepime. The rights for ceftobiprole have been transferred back to Basilea from Cilag GmbH International, a Johnson & Johnson company, in February 2011.
Disease: severe community-acquired and hospital-acquired pneumonia
Details:
- • On September 28, 2017, Basilea Pharmaceutica International has entered into a license agreement with China Resources Gosun Pharmaceutical for Zevtera® (ceftobiprole) in China, Hong Kong and Macao. Under the terms of the agreement, CR Gosun is granted an exclusive license to develop, manufacture and to commercialize ceftobiprole in the Territory.
Financial terms:
- Basilea will receive an execution payment of CHF 3 million and is eligible to receive up to approximately CHF 145 million additional payments upon achievement of pre-specified regulatory and commercial milestones.
- CR Gosun will bear all costs for regulatory and development activities, including the conduct of clinical studies necessary for obtaining marketing authorization in the Territory. Basilea will initially supply CR Gosun at a transfer price and will be eligible for tiered double-digit royalties on product sales once CR Gosun manufactures ceftobiprole itself.
Latest news:
Is general: Yes
